Creso Pharma receives approval for cannabis acquisition
Creso Pharma Limited (ASX:CPH) has today announced that regulatory approval from ASX for the shareholder meeting document to approve the transaction with Kunna Canada Ltd has now been received.
Enclosed is a Notice of Meeting for a shareholders’ meeting to be held on 16 October 2018 at 10:00am (WST). Subject to the receipt of shareholder approval, the company anticipates completing the Kunna acquisition in mid-October 2018 and thereafter immediately advancing its business plan in Colombia.
Since first executing the agreement relating to the Kunna acquisition, Colombia has cemented its place as the international jurisdiction of choice for low cost, high quality cannabis production. There have been multiple international (mainly Canadian) companies that have announced transactions to enter Colombia, including from the world’s largest cannabis company Canopy Growth Corp in a transaction worth up to US$96 million.
The company believes these transactions vindicate CPH’s move into Colombia and should provide investors with additional comfort in relation to CPH’s strategy.
Retraction regarding Quarterly Activities Report
CPH notes that, on 31 July 2018, the company’s Quarterly Activities Report stated that the company had completed the Kunna acquisition.
The company intended for this to disclose that due diligence had been completed in relation to the Kunna acquisition. Completion has not occurred, and these statements are hereby retracted by CPH. As noted above, completion is now anticipated to occur in mid-October 2018 (subject to the receipt of shareholder approval).
Once its acquisition of Kunna is finalised, CPH will be one of only a few companies in the world — and the only medicinal cannabis company listed on the ASX — with the capacity to commercially cultivate medicinal-grade cannabis in Colombia.
In June, the company announced that Kunna S.A.S, the wholly owned Colombian subsidiary of Kunna Canada Ltd, had been granted a licence to cultivate medicinal cannabis in the country.
However, it is an early stage of this company’s development in these countries and if considering this stock for your portfolio, you should take all public information into account and seek professional financial advice.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.